Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
The oncologist（2023）
摘要
NCT03508011.
更多查看译文
关键词
senaparib,inhibitor,solid tumors,pharmacokinetics
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要